CymaBay Therapeutics competitors
CymaBay Therapeutics Competitors include Reata Pharmaceuticals, Ironwood Pharmaceuticals, Biogen and MyoKardia.
Add company...
You can compare up to 12 companies. Please remove a company to add a new one
| Save ComparisonClear all |  CymaBay Therapeutics CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. |  Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. |  Ironwood Pharmaceuticals Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases. |  Biogen Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases. |  MyoKardia MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. |
Founding Date | Founding Date 1991 | Founding Date 2002 | Founding Date N/A | Founding Date 1978 | Founding Date 2012 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Newark, US HQ | Locations Irving, US HQ | Locations Cambridge, US HQ | Locations Cambridge, US HQ | Locations South San Francisco, US HQ |
Employees | Employees 2624% increase | Employees 12332% increase | Employees 730 | Employees 7,8007% increase | Employees 1024% increase |
Valuation ($) | Valuation ($) 791 m | Valuation ($) N/A | Valuation ($) 2.1 b | Valuation ($) 63.7 b | Valuation ($) 2.2 b |
Twitter followers | Twitter followers N/A | Twitter followers 418 | Twitter followers 3.1 k | Twitter followers 19.4 k | Twitter followers 387 |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $346.6m (FY, 2018) | Revenue (est.) $11.4b (FY, 2016) | Revenue (est.) N/A |
Net income | Net income ($72.5m) (FY, 2018) | Net income ($80.5m) (FY, 2018) | Net income ($282.4m) (FY, 2018) | Net income $3.7b (FY, 2016) | Net income ($67.7m) (FY, 2018) |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products 4 (FY, 2016) | Phase I Trials Products 2 (FY, 2017) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products 10 (FY, 2016) | Phase II Trials Products 1 (FY, 2017) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products 2 (FY, 2016) | Phase III Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 247.5m | Total funding raised $ 300m | Total funding raised $ 284m | Total funding raised N/A | Total funding raised $ 98m |
For sources of this data, please see the company profileDownload Excel
View company profiles
Reata Pharmaceuticals
HQ
Irving, US
Employees
123↑ 32% increase
Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.
View companyIronwood Pharmaceuticals
HQ
Cambridge, US
Employees
730
Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
View companyBiogen
HQ
Cambridge, US
Employees
7,800↑ 7% increase
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
View companyMyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
View company